VBI Vaccines News and Activities

VBI Vaccines is a company listed under the stock ticker VBIV (US).

View the org chart displaying its 17 main executives

Most searched biographies at VBI Vaccines

• Jeff Baxter, President and Chief Executive Officer and Director
• Steven Gillis, Chairman of the Board
• Joanne Cordeiro, Director

Create your alert
to follow the executive moves at VBI Vaccines.

VBI Vaccines has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by VBI Vaccines

• VBI Vaccines Provides an Update on its Restructuring Proceedings and Announces Partial Revocation Order from the British Columbia Securities Commission - VBI Vaccines
• VBI Vaccines Issues Voluntary Nationwide Recall of All PreHevbrio Vaccine Due to Discontinuation of Company Operations - VBI Vaccines
• VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives - VBI Vaccines
• VBI Vaccines Provides an Update on its Restructuring Proceedings - VBI Vaccines
• Press Releases - VBI Vaccines
• VBI Vaccines Announces Results of Annual General Meeting - VBI Vaccines
• VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients - VBI Vaccines
• VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients - VBI Vaccines
• VBI Vaccines Reports First Quarter 2024 Financial Results - VBI Vaccines
• VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - VBI Vaccines
• View more press releases Close

Social media about VBI Vaccines

• VBI Vaccines on Wikipedia, Google News & Yahoo Finance
• VBI Vaccines on LinkedIn, X (Twitter) & YouTube